Research Article
Volume 5 Issue 3 - 2020
A Narrative Review of Selected Literature on the Management of Thromboembolism in Patients with COVID-19
Shafi U Bhuhiyan1,2*, Housne A Begum2,3, Khalid Niaz2, Eiman M Ali2, Ishraq Tashkandi2, Elahe Ranjbar2, Mariano K Rubharajan2
and Hana'a Badran2
1University of Toronto, Toronto, ON, Canada
2Ryerson University, Toronto, ON, Canada
3McMaster University, Hamilton, ON, Canada
*Corresponding Author: Shafi U Bhuiyan, University of Toronto and Ryerson University, Toronto, ON, Canada.
Received: November 02, 2020; Published: February 27, 2021


Introduction: Novel coronavirus (COVID-19) infection is reportedly associated with a high risk of thromboembolic complications. This review provides an overview of the current knowledge about the management of venous thromboembolism in coronavirus disease.

Methods: An online search of literature through PubMed and google scholar was done using the term “COVID-19”, “treatment”, “thromboembolism”, “antiplatelet”, “antithrombolytics” and “anticoagulants”. Articles were chosen for inclusion based on their relevance to coagulopathy and thrombosis in coronavirus disease and anticoagulant therapy. Reference lists were also reviewed to select additional relevant articles.

Results: Average incidence of thromboembolism in hospitalized COVID-19 patients varied between 25-53%. D-dimer was the most frequent coagulopathy marker used to assess the severity of the disease. If there is any suspicion of deep vein thrombosis (DVT), diagnosis is primarily based on bedside clinical examinations and then objectively confirmed by imaging studies. Low-molecular-weight heparin (LMWH) is reported as the first line drug in the treatment of thromboembolism associated with COVID-19. There is currently no high quality evidence for administering thrombolytic for the treatment of COVID-19 pulmonary microthrombi. Prophylaxis is considered in patients at greatest risk, especially those with reduced mobility and a previous history of venous thromboembolism (VTE) or active malignancy. The selection of drugs and dosing should be considered based on recommendations of the current standards.

Conclusion: Anticoagulant therapy with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting Sepsis-Induced Coagulopathy (SIC) criteria or with markedly elevated D-dimer. Despite the use of anticoagulant prophylaxis, the thrombotic risk is high and optimum dosage of anticoagulation is not yet established.

Keywords: Coagulopathy; Coronavirus Disease 2019; Hypercoagulability; Thromboembolism


  1. WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard (2020).
  2. Cui S., et al. “Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia”. Journal of Thrombosis and Haemostasis 6 (2020): 1421-1424.
  3. Tang N., et al. “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy”. Journal of Thrombosis and Haemostasis 5 (2020): 1094-1099.
  4. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. The Journal of the American Medical Association 11 (2020): 1061-1069.
  5. Guan WJ., et al. “Clinical characteristics of coronavirus disease 2019 in China”. The New England Journal of Medicine 382 (2020): 1708-1720.
  6. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 497-506.
  7. Zhang L., et al. “D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19”. Journal of Thrombosis and Haemostasis 6 (2020): 1324-1329.
  8. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet 395 (2020): 1054-1062.
  9. Fogarty H., et al. “COVID19 coagulopathy in Caucasian patients”. British Journal of Haematology 6 (2020): 1044-1049.
  10. Liang W., et al. “Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19”. JAMA Internal Medicine 8 (2020): 1081-1089.
  11. Lippi G., et al. “Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis”. Clinica Chimica Acta 506 (2020): 145-148.
  12. Yang X., et al. “Thrombocytopenia and its association with mortality in patients with COVID-19”. Journal of Thrombosis and Haemostasis 18 (2020): 1469-1472.
  13. Gao Y., et al. “Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19”. Journal of Medical Virology (2020): 1-6.
  14. Lagadinou M., et al. “Prognosis of COVID-19: Changes in laboratory parameters”. Le Infezioni in Medicina 1 (2020): 89-95.
  15. Llitjos JF., et al. “High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients”. The Journal of Thrombosis and Haemostasis (2020): 1-4.
  16. Maldonado E., et al. “Antithrombotic Therapies in COVID-19 Disease: a Systematic Review”. Journal of General Internal Medicine 9 (2020): 2698-2706.
  17. Chi G., et al. “Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis”. Journal of Clinical Medicine 8 (2020): 2489.
  18. Hasan SS., et al. “Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review”. The Journal of Thrombosis and Thrombolysis 3 (2020): 1-8.
  19. Lu YF., et al. “A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19”. International Journal of Infectious Diseases (2020).
  20. Zhang C., et al. “Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis”. Frontiers in Cardiovascular Medicine 7 (2020): 151.
  21. Kunutsora SK and Laukkanenc JA. “Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis”. Thrombosis Research 196 (2020): 27-30.
  22. Iba T., et al. “Coagulopathy of Coronavirus Disease 2019”. Critical Care Medicine 9 (2020): 1358-1364.
  23. Al-Ani F., et al. “Thrombosis risk associated with COVID-19 infection. A scoping review”. Thrombosis Research 192 (2020): 152-160.
  24. Wang T., et al. “Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19”. The Lancet Haematology 5 (2020): e362-e363.
  25. Aryal MR., et al. “Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment”. Current Cardiology Reports 22 (2020): 52.
  26. Connors JM and Levy JH. “COVID-19 and its implications for thrombosis and anticoagulation”. Blood23 (2020): 2033-2040.
  27. Klok FA., et al. “Incidence of thrombotic complications in critically ill ICU patients with COVID-19”. Thrombosis Research 191 (2020): 145-147.
  28. Kollias A., et al. “Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action”. British Journal of Haematology 5 (2020): 846-847.
  29. Costanzo L., et al. “Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia”. Journal of Vascular Surgery: Venous and Lymphatic Disorders 5 (2020): 711-716.
  30. Breakey N and Escher R. “D-dimer and mortality in COVID-19: a self-fulfilling prophecy or a pathophysiological clue?” Swiss Medical Weekly 150 (2020): w20293.
  31. Tang N., et al. “Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia”. Journal of Thrombosis and Haemostasis 4 (2020): 844-847.
  32. Iba T., et al. “Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation”. Journal of Thrombosis and Haemostasis 11 (2019): 1989-1994.
  33. Thachil J., et al. “ISTH interim guidance on recognition and management of coagulopathy in COVID-19”. Journal of Thrombosis and Haemostasis 5 (2020): 1023-1026.
  34. Spyropoulos AC., et al. “Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19”. Journal of Thrombosis and Haemostasis 8 (2020): 1859-1865.
  35. Poterucha TJ., et al. “More than an anticoagulant: Do heparins have direct anti-inflammatory effects?” The Journal of Thrombosis and Haemostasis 3 (2017): 437-444.
  36. Watson RA., et al. “Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system”. Hospital Practice (1995): 1-11.
  37. Sivaloganathan H., et al. “COVID-19 mortality in patients on anticoagulants and antiplatelet agents”. British Journal of Haematology (2020): 1111.
  38. Wang J., et al. “Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series”. Journal of Thrombosis and Haemostasis 7 (2020): 1752-1755.
  39. Chatterjee S., et al. “Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis”. The Journal of the American Medical Association23 (2014): 2414-2421.
  40. Barnes GD., et al. “Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum”. Journal of Thrombosis and Haemostasis 1 (2020): 72-81.
  41. Bikdeli B., et al. “COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review”. Journal of the American College of Cardiology 23 (2020): 2950-2973.
  42. Zhai Z., et al. “Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines”. Thrombosis and Haemostasis 120 (2020): 937-948.
Citation: Shafi U Bhuiyan., et al. “A Narrative Review of Selected Literature on the Management of Thromboembolism in Patients with COVID-19”. EC Emergency Medicine and Critical Care 5.3 (2021): 17-26.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

May Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the May issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before June 08, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.